Webinar: Non-invasive, single session treatment options for NMSC
In this webinar, A/Prof Chris Baker and A/Prof Sid Baxi discuss non-invasive, single session treatment options for non-melanoma skin cancer.
HealthCert Education
In this webinar (delivered in collaboration with OncoBeta), leading global experts A/Prof Chris Baker and A/Prof Siddhartha Baxi discuss the latest research, real-world outcomes, and the importance of clinical collaboration in delivering advanced non-invasive treatment options to non-melanoma skin cancer (NMSC) patients.
This webinar is tailored for doctors who wish to expand their knowledge of the latest NMSC treatment options now available to Australian patients.
Watch the full recording below to gain an understanding of the clinical applications of non-invasive treatments for skin cancer, explore the latest research and evidence-based outcomes, learn which patients are candidates for non-invasive treatments, and gain the know-how to integrate the treatments into your clinical work.
This is an insightful and educational webinar from two global experts in dermatology and oncology — a must-watch for GPs doing skin cancer work.
Watch the full webinar recording now:
Download the presentation slide deck here.
Interested in skin cancer medicine? Learn more with HealthCert's university-assured and CPD-accredited Professional Diploma program in Skin Cancer Medicine, delivered online or with optional workshops.
A/Prof Chris Baker is a globally recognised Dermatologist and former President of the Australasian College of Dermatologists. He is a leading authority on treatment options for non-melanoma skin cancer (NMSC) and is extensively published in the field of NMSC. He is the current Director of Dermatology at St Vincent's Hospital Melbourne and past President of the Skin Health Institute.
A/Prof Siddhartha (Sid) Baxi is a highly regarded Radiation Oncologist based on the Gold Coast. He has played a pivotal role in advancing non-invasive skin cancer treatments, most recently through his role as local PI on the global EPIC-Skin prospective post-market study of Rhenium-SCT- investigating real-world outcomes of Rhenium-SCT. This was the first study to include Australian patients.
Engaging with this blog can help meet your annual
|
How to claim your CPD hours
|
Watch another webinar recording: Treatment strategies for actinic keratosis